The global Male Infertility Market size is expected to reach USD 5.03 billion by 2027, expanding at a CAGR of 4.7% over the forecast period, according to a new report by Grand View Research, Inc. Advancements in diagnostic tests and increasing infertility in males are some of the major factors driving the market for male infertility. In addition, lifestyle-associated diseases causing infertility, rising obesity, and growing aging population are likely to boost the market growth during the forecast period. In U.S., one-third of infertility cases are due to female factors, one third due to male factors, and the remaining one third is unknown.
DNA fragmentation technique emerged the
largest test segment in the market in 2019 and is expected to maintain its lead
during the forecast period. Increasing adoption in developed countries and high
cost due to higher sensitivity and reliable analysis of sperm DNA integrity are
the key factors driving the segment.
On the basis of treatment, the Assisted
Reproductive Technology (ART) and Varicocele Surgery segment dominated the
market for male infertility in 2019 due to its high success rate.
Intracytoplasmic sperm injection (ICSI) and in vitro fertilization (IVF) are
the most commonly used ARTs. Medications include hormonal therapy and
corticosteroids, however they are effective in very few cases.
Partnerships and agreements among key
manufacturers are expected to boost the market growth in the coming years. For
instance, in July 2019, Vitrolife entered into a collaboration with Prime Tech
for the development and exclusive marketing of the Piezo technique, for
improved Intracytoplasmic Sperm Injection (ICSI) procedure in human IVF
globally except Malaysia, Thailand, and Japan. Additionally, Vitrolife will
initiate the regulatory approval procedures in various markets for the future
commercialization of the technology.
Request a sample copy or view summary of
this report@ https://www.grandviewresearch.com/industry-analysis/male-infertility-market
Further key
findings from the study suggest:
- Based on test, DNA fragmentation technique dominated the market in
2019 and is estimated to witness significant growth over the forecast
period
- Oxidative stress analysis test is gaining popularity due to the
accurate determination of reactive oxygen species. In March 2018, Aytu
BioScience, Inc. received registration from COFEPRIS in Mexico for MiOXSYS
System, which is used for diagnosing male infertility
- Europe dominated the male infertility market in 2019 and is
expected to maintain its lead during the forecast period due to high
adoption of costlier treatment, strong diagnosis rate, and increased
awareness
- Asia Pacific is projected to witness substantial growth over the
forecast period owing to increasing investment by several clinics and
pharmaceutical companies and growing healthcare expenditure
- Some key players of the market are Bayer Healthcare, Inc.; EMD
Sereno; Aytu BioScience, Inc.; Halotech DNA SL; Intas Pharmaceuticals
Ltd.; Cadila Healthcare Ltd.; Andrology Solutions; and SCSA diagnostics,
Inc.
About Us:
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco. The
company provides syndicated research reports, customized research reports, and
consulting services. To help clients make informed business decisions, the
company offers market intelligence studies ensuring relevant and fact-based
research across a range of industries including technology, chemicals,
materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
No comments:
Post a Comment